Drug-Resistant Staph a Growing Concern

摘要：That‘s the finding in three new studies on MRSA (methicillin-resistant Staphylococcus aureus) bacteria。 It‘s tougher to treat than most strains of Staphylococcus aureus because it‘s immune to some commonly used antibiotics。Dror Marchaim, MD, of Israel‘s Tel-Aviv Medical Center analyzed 21 s......

• 临床快报
• 药市动态
• 违法广告
• 医保动态
• 药品价格
• 流感疫情
• 保健常识
• 妇科课堂
• 医改动态

Sept. 28, 2006 -- Drug-resistant staph infections -- called MRSA -- are common, tough to treat, and may become an even bigger problem unless this "super bug" can be squashed.

That's the finding in three new studies on MRSA (methicillin-resistant Staphylococcus aureus) bacteria.

The studies were presented today in San Francisco, at the American Society for Microbiology's 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy.

MRSA causes infections in different parts of the body. It's tougher to treat than most strains of Staphylococcus aureus because it's immune to some commonly used antibiotics. That's why it's sometimes called a "super bug."

MRSA usually causes mild skin infections, such as pimples or boils. But it can also result in more serious skin infections or infect surgical wounds, the bloodstream, and organs.

While most MRSA infections aren't serious, some can be life-threatening.

Many public health experts are alarmed by the spread of tough strains of the bacteria.

Health Threat

MRSA can be deadly, costly, and may be poised to do even more damage, according to the first study presented in San Francisco.

Dror Marchaim, MD, of Israel's Tel-Aviv Medical Center analyzed 21 studies involving 1,131 MRSA patients and 1,587 patients with drug-sensitive Staphylococcus aureus.

MRSA patients fared worse, across the board, he found.

They were 36% more likely to die, stayed in the hospital seven days longer, and their hospital bill was $7,250 to $11,500 higher, Marchaim says.

Marchaim predicts that if MRSA replaces drug-sensitive Staphylococcus aureus, "this will add annually 2,700 cases of death, 210,000 days of hospitalization, and $310 million to hospital expenditures.

"Strategies to better control and treat MRSA are required," Marchaim writes.

发布日期：2006-9-29

• 相关主题关键字：
• Drug-Resistant
• Staph
• Growing
• Concern

输入您的搜索字词 提交搜索表单
互联网 本站 企业频道